The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
The Indoleamine 2,3-Dioxygenase Pathway Is Essential for Human Plasmacytoid Dendritic Cell-Induced Adaptive T Regulatory Cell Generation
Open accessAbstract
Human plasmacytoid dendritic cells (PDCs) can drive naive, allogeneic CD4+CD25− T cells to differentiate into CD4+CD25+Foxp3+ regulatory T cells (Tregs). However, the intracellular mechanism or mechanisms underlying PDC-induced Treg generation are unknown. In this study, we show that human PDCs express high levels of IDO, an intracellular enzyme that catabolizes tryptophan degradation. Triggering of TLR 9 with CpG oligodeoxynucleotides activates PDCs to up-regulate surface expression of B7 ligands and HLA-DR Ag, but also significantly increases the expression of IDO and results in the generation of inducible Tregs from CD4+CD25− T cells with potent suppressor cell function. Blocking IDO activity with the pharmacologic inhibitor 1-methyl-d-tryptophan significantly abrogates PDC-driven inducible Treg generation and suppressor cell function. Adding kynurenine, the immediate downstream metabolite of tryptophan, bypasses the 1-methyl-d-tryptophan effect and restores PDC-driven Treg generation. Our results demonstrate that the IDO pathway is essential for PDC-driven Treg generation from CD4+CD25− T cells and implicate the generation of kynurenine pathway metabolites as the critical mediator of this process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
Groux, H., O'Garra, A., Bigler, M., Rouleau, M., Antonenko, S., de Vries, J. E., & Roncarolo, M. G. (1997) · Nature · doi:10.1038/39614 · Cited by 3,588
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Self-citationKadowaki, N., Ho, S., Antonenko, S., de Waal Malefyt, R., Kastelein, R. A., Bazan, F., & Liu, Y.-J. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.863 · Cited by 1,964
Plasmacytoid dendritic cells in immunity
Colonna, M., Trinchieri, G., & Liu, Y.-J. (2004) · Nature Immunology · doi:10.1038/ni1141 · Cited by 1,678
IPC: Professional Type 1 Interferon-Producing Cells and Plasmacytoid Dendritic Cell Precursors
Liu, Y.-J. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115633 · Cited by 1,625
Modulation of tryptophan catabolism by regulatory T cells
Fallarino, F., Grohmann, U., Hwang, K. W., Orabona, C., Vacca, C., Bianchi, R., Belladonna, M. L., Fioretti, M. C., Alegre, M.-L., & Puccetti, P. (2003) · Nature Immunology · doi:10.1038/ni1003 · Cited by 1,374
Munn, D. H., Sharma, M. D., Baban, B., Harding, H. P., Zhang, Y., Ron, D., & Mellor, A. L. (2005) · Immunity · doi:10.1016/j.immuni.2005.03.013 · Cited by 1,272
Self-citationIn Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes
Tang, Q., Henriksen, K. J., Bi, M., Finger, E. B., Szot, G., Ye, J., Masteller, E. L., McDevitt, H., Bonyhadi, M., & Bluestone, J. A. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040139 · Cited by 1,221
CTLA-4–Ig regulates tryptophan catabolism in vivo
Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., Candeloro, P., Belladonna, M. L., Bianchi, R., Fioretti, M. C., et al. (2002) · Nature Immunology · doi:10.1038/ni846 · Cited by 1,161
Frumento, G., Rotondo, R., Tonetti, M., Damonte, G., Benatti, U., & Ferrara, G. B. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020121 · Cited by 1,133
Cited by
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
Mezrich, J. D., Fechner, J. H., Zhang, X., Johnson, B. P., Burlingham, W. J., & Bradfield, C. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903670 · Cited by 1,601
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
Munn, D. H., & Mellor, A. L. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.001 · Cited by 1,037
Self-citationMetabolism of immune cells in cancer
Leone, R. D., & Powell, J. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0273-y · Cited by 877
François, M., Romieu-Mourez, R., Li, M., & Galipeau, J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.189 · Cited by 694
Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 634
Self-citationWainwright, D. A., Chang, A. L., Dey, M., Balyasnikova, I. V., Kim, C. K., Tobias, A., Cheng, Y., Kim, J. W., Qiao, J., Zhang, L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0514 · Cited by 576
Innate Immune Recognition of Cancer
Woo, S.-R., Corrales, L., & Gajewski, T. F. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112043 · Cited by 571
Akdis, M., & Akdis, C. A. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.12.1088 · Cited by 565
How Tolerogenic Dendritic Cells Induce Regulatory T Cells
Maldonado, R. A., & von Andrian, U. H. (2010) · Advances in Immunology · doi:10.1016/b978-0-12-380995-7.00004-5 · Cited by 541
Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-204 · Cited by 534
Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment?
Guerin, L. R., Prins, J. R., & Robertson, S. A. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp004 · Cited by 498
Dendritic Cell Regulation of T Helper Cells
Yin, X., Chen, S., & Eisenbarth, S. C. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101819-025146 · Cited by 447
Tumor-Infiltrating Dendritic Cells in Cancer Pathogenesis
Tran Janco, J. M., Lamichhane, P., Karyampudi, L., & Knutson, K. L. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403134 · Cited by 440
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
Löb, S., Königsrainer, A., Rammensee, H.-G., Opelz, G., & Terness, P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2639 · Cited by 421
Human T Regulatory Cell Therapy: Take a Billion or So and Call Me in the Morning
Riley, J. L., June, C. H., & Blazar, B. R. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.006 · Cited by 412
Self-citationRole of Treg in immune regulation of allergic diseases
Palomares, O., Yaman, G., Azkur, A. K., Akkoc, T., Akdis, M., & Akdis, C. A. (2010) · European Journal of Immunology · doi:10.1002/eji.200940045 · Cited by 394
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)07003-x · Cited by 386
Matteoli, G., Mazzini, E., Iliev, I. D., Mileti, E., Fallarino, F., Puccetti, P., Chieppa, M., & Rescigno, M. (2010) · Gut · doi:10.1136/gut.2009.185108 · Cited by 378
Concise Review: Hitting the Right Spot with Mesenchymal Stromal Cells
Tolar, J., Le Blanc, K., Keating, A., & Blazar, B. R. (2010) · Stem Cells · doi:10.1002/stem.459 · Cited by 376
Self-citationThéate, I., van Baren, N., Pilotte, L., Moulin, P., Larrieu, P., Renauld, J.-C., Hervé, C., Gutierrez-Roelens, I., Marbaix, E., Sempoux, C., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0137 · Cited by 363
Sisirak, V., Faget, J., Gobert, M., Goutagny, N., Vey, N., Treilleux, I., Renaudineau, S., Poyet, G., Labidi-Galy, S. I., Goddard-Leon, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3468 · Cited by 345
Lactate-Lactylation Hands between Metabolic Reprogramming and Immunosuppression
Chen, L., Huang, L., Gu, Y., Cang, W., Sun, P., & Xiang, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911943 · Cited by 344
Targeting the indoleamine 2,3-dioxygenase pathway in cancer
Moon, Y. W., Hajjar, J., Hwu, P., & Naing, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0094-9 · Cited by 336
Cancer cell metabolism and antitumour immunity
De Martino, M., Rathmell, J. C., Galluzzi, L., & Vanpouille-Box, C. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-024-01026-4 · Cited by 327
Trial watch: IDO inhibitors in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A., Sautès-Fridman, C., Tartour, E., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 326
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
Saleh, R., & Elkord, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.017 · Cited by 292
The role of decidual immune cells on human pregnancy
Liu, S., Diao, L., Huang, C., Li, Y., Zeng, Y., & Kwak-Kim, J. Y. H. (2017) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2017.10.045 · Cited by 308
Dasgupta, S., Erturk-Hasdemir, D., Ochoa-Reparaz, J., Reinecker, H.-C., & Kasper, D. L. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.03.006 · Cited by 292
Immune control by amino acid catabolism during tumorigenesis and therapy
Lemos, H., Huang, L., Prendergast, G. C., & Mellor, A. L. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0106-z · Cited by 274
Chung, D. J., Rossi, M., Romano, E., Ghith, J., Yuan, J., Munn, D. H., & Young, J. W. (2009) · Blood · doi:10.1182/blood-2008-11-191197 · Cited by 262
Self-citationJürgens, B., Hainz, U., Fuchs, D., Felzmann, T., & Heitger, A. (2009) · Blood · doi:10.1182/blood-2008-12-195073 · Cited by 176
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Botticelli, A., Cerbelli, B., Lionetto, L., Zizzari, I., Salati, M., Pisano, A., Federica, M., Simmaco, M., Nuti, M., & Marchetti, P. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1595-3 · Cited by 124
Food Fight: Role of Itaconate and Other Metabolites in Antimicrobial Defense
Luan, H. H., & Medzhitov, R. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.013 · Cited by 130
Min, S.-Y., Yan, M., Kim, S. B., Ravikumar, S., Kwon, S.-R., Vanarsa, K., Kim, H.-Y., Davis, L. S., & Mohan, C. (2015) · Journal of Inflammation · doi:10.1186/s12950-015-0097-9 · Cited by 87
Complexity of immune responses to AAV transgene products – Example of factor IX
Herzog, R. W. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.05.006 · Cited by 60
Biswas, M., Sarkar, D., Kumar, S. R. P., Nayak, S., Rogers, G. L., Markusic, D. M., Liao, G., Terhorst, C., & Herzog, R. W. (2015) · Blood · doi:10.1182/blood-2014-09-599266 · Cited by 70
Moeinabadi-Bidgoli, K., Babajani, A., Yazdanpanah, G., Farhadihosseinabadi, B., Jamshidi, E., Bahrami, S., & Niknejad, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112026 · Cited by 70
The metabolic dialogue between intratumoural microbes and cancer: implications for immunotherapy
Situ, Y., Zhang, P., Zhang, C., Jiang, A., Zhang, N., Zhu, L., Mou, W., Liu, Z., Wong, H. Z. H., Zhang, J., et al. (2025) · eBioMedicine · doi:10.1016/j.ebiom.2025.105708 · Cited by 45
Mezrich, J. D., Nguyen, L. P., Kennedy, G., Nukaya, M., Fechner, J. H., Zhang, X., Xing, Y., & Bradfield, C. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044547 · Cited by 40
Wang, Y., Hu, G.-F., & Wang, Z. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s136259 · Cited by 21
Metadata
- Authors
- Chen, W., Liang, X., Peterson, A. J., Munn, D. H., & Blazar, B. R.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-10
- Volume
- 181
- Issue
- 8
- Pages
- 5396-5404
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2157800695
- Cited by
- 453
- References
- 56
- FWCI
- 12.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.